172 related articles for article (PubMed ID: 7719243)
1. Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma.
Motokura T; Kobayashi Y; Fujita A; Nakamura Y; Taniguchi T; Uchimaru K; Asano S
Leuk Lymphoma; 1995 Jan; 16(3-4):355-62. PubMed ID: 7719243
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
Srivastava MD; Srivastava A; Srivastava BI
Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
[TBL] [Abstract][Full Text] [Related]
3. Elevated soluble CD8 antigen and soluble interleukin-2 receptors in the sera of patients with juvenile rheumatoid arthritis.
Lipnick RN; Sfikakis PP; Klipple GL; Tsokos GC
Clin Immunol Immunopathol; 1993 Jul; 68(1):64-7. PubMed ID: 8513595
[TBL] [Abstract][Full Text] [Related]
4. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors.
Orditura M; De Vita F; Roscigno A; Auriemma A; Infusino S; Catalano G
Int J Mol Med; 1998 Jul; 2(1):75-9. PubMed ID: 9854147
[TBL] [Abstract][Full Text] [Related]
5. Soluble interleukin 2 receptor and soluble CD8 levels in previously treated human immunodeficiency virus-negative hemophiliacs multiply transfused with a monoclonal antibody-purified factor VIII concentrate.
Smid WM; Martens A; van der Meer J; Hegge-Paping CS; Halie MR
Transfusion; 1997 Jan; 37(1):86-9. PubMed ID: 9024495
[TBL] [Abstract][Full Text] [Related]
6. Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.
Spronk PE; ter Borg EJ; Huitema MG; Limburg PC; Kallenberg CG
Ann Rheum Dis; 1994 Apr; 53(4):235-9. PubMed ID: 8203951
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Beguin Y; Lampertz S; De Groote D; Igot D; Malaise M; Fillet G
Leukemia; 1993 Dec; 7(12):2019-25. PubMed ID: 8255102
[TBL] [Abstract][Full Text] [Related]
8. Behavior of serum soluble interleukin-2 receptor, soluble CD8 and soluble CD4 in the early phases of acute pancreatitis.
Pezzilli R; Billi P; Gullo L; Beltrandi E; Maldini M; Mancini R; Incorvaia L; Miglioli M
Digestion; 1994; 55(4):268-73. PubMed ID: 8063032
[TBL] [Abstract][Full Text] [Related]
9. Serum TNF-alpha, sCD8 and sIL-2R levels in childhood tuberculosis.
Barlan IB; Başaran MM; Bakir M; Tükenmez F; Bekiroğlu N
Infection; 1995; 23(4):237-9. PubMed ID: 8522383
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
11. Soluble interleukin-2 receptor and soluble CD8 in serum and cerebrospinal fluid during human immunodeficiency virus-associated neurologic disease.
Griffin DE; McArthur JC; Cornblath DR
J Neuroimmunol; 1990 Jul; 28(2):97-109. PubMed ID: 2113934
[TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1.
De Rie MA; Zonneveld IM; Witkamp L; Van Lier RA; Out TA; Bos JD
Acta Derm Venereol; 1996 Sep; 76(5):357-60. PubMed ID: 8891007
[TBL] [Abstract][Full Text] [Related]
13. T-cell evaluation in patients with colon cancer: dinitrochlorobenzene skin testing versus plasma levels of sIL-2r and sCD8.
Bleeker WA; de Ley L; Oeseburg HB; Martens A; Mulder NH; Hermans J; Plukker JT
Ann Surg Oncol; 1998; 5(3):209-12. PubMed ID: 9607619
[TBL] [Abstract][Full Text] [Related]
14. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
[TBL] [Abstract][Full Text] [Related]
15. The effects of nonsteroidal antiinflammatory drug therapy in early rheumatoid arthritis on serum levels of soluble interleukin 2 receptor, CD4, and CD8.
Dooley MA; Cush JJ; Lipsky PE; Dawson DV; Pisetsky DS
J Rheumatol; 1993 Nov; 20(11):1857-62. PubMed ID: 8308770
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
Ann Oncol; 1992 Sep; 3 Suppl 4():49-52. PubMed ID: 1333270
[TBL] [Abstract][Full Text] [Related]
17. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
18. Serum soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in Crohn's disease, celiac disease, and systemic lupus erythematosus.
Srivastava MD; Rossi TM; Lebenthal E
Res Commun Mol Pathol Pharmacol; 1995 Jan; 87(1):21-6. PubMed ID: 7735726
[TBL] [Abstract][Full Text] [Related]
19. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia.
Kamihira S; Atogami S; Sohda H; Momita S; Yamada Y; Tomonaga M
Cancer; 1994 Jun; 73(11):2753-8. PubMed ID: 8194016
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of CD8 antigen and soluble interleukin 2 receptors in patients with B cell chronic lymphocytic leukemia.
Musolino C; Di Cesare E; Alonci A; Allegra A; Orlando A; Grosso P; Squadrito G
Acta Haematol; 1991; 85(2):57-61. PubMed ID: 1902614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
